Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA NephropathyGlobeNewsWire • 02/17/23
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/16/23
Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is CriticalSeeking Alpha • 01/26/23
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022GlobeNewsWire • 10/26/22
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/20/22
Here's Why Travere (TVTX) is Poised for a Turnaround After Losing 22.2% in 4 WeeksZacks Investment Research • 10/17/22
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA NephropathyGlobeNewsWire • 10/13/22
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual SymposiumGlobeNewsWire • 08/25/22
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA NephropathyGlobeNewsWire • 08/22/22
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA NephropathyBusiness Wire • 08/22/22
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA CongressGlobeNewsWire • 05/17/22
Travere Therapeutics' (TVTX) CEO Eric Dube on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22